CliffBio
biologic

Admelog

insulin lispro

Loss of exclusivityOctober 2030projected — 12-year biologic exclusivity estimate
CompanySanofi-Aventis U.S. LLC

Drug detail

Brand nameAdmelog
Active ingredientinsulin lispro
Strength300UNITS/3ML (100UNITS/ML)
Dosage formInjection
RouteIntravenous, Subcutaneous
ModalityBiologic
FDA approvalOctober 2018
Marketing statusRx

More from Sanofi-Aventis U.S. LLC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Admelog patent cliff — loss of exclusivity October 2030 | CliffBio